# Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer

> **NCT03323658** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 24 (actual)

## Conditions studied

- Breast Atypical Ductal Hyperplasia
- Breast Atypical Lobular Hyperplasia
- Breast Ductal Carcinoma In Situ
- Breast Lobular Carcinoma In Situ
- Invasive Breast Carcinoma

## Interventions

- **DRUG:** Bexarotene
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT03323658
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-15
- **Primary completion:** 2021-08-03
- **Final completion:** 2022-03-25
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03323658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03323658, "Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03323658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*